Tiered Royalties Become The Majority In Biopharma Licensing As High-End Rates Rebound
Dublin, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Royalty Rates in Pharmaceutical and Biotechnology Licensing Deals 2015-2026 ResearchAndMarkets.com' s offering, providing an evidence-based benchmark of royalty rates and financial terms across more than 1,600 pharmaceutical and biotechnology licensing transactions.
New analysis from Current Partnering highlights a continued shift towards tiered royalty structures in pharmaceutical and biotechnology licensing agreements.
Analysis of more than 770 royalty-bearing licensing deals announced between January 2020 and August 2026 found that 60% of qualifying deals in 2026 use tiered royalty structures, compared with around four in ten in 2020.
The findings point to a continuing shift towards deal structures that allow licensors to participate more substantially in future commercial success as sales increase.
Higher royalty rates have also become more prominent following a comparatively subdued market in 2024. Approximately 40% of qualifying 2026 licensing deals include royalty rates of 15% or more, while the median disclosed royalty reference rate currently stands at approximately 12%.
“The most interesting development is not simply the level of royalty rates, but how the economics of licensing agreements are being structured,” said Claire Nicholson, CEO of Current Partnering.
“Tiered royalties give both sides greater flexibility in allocating future value, while our analysis also continues to show significant differences according to development stage, asset characteristics and the wider economics of the transaction.”
The analysis included in the report found a clear premium associated with more advanced assets, reinforcing the importance of using genuinely comparable transactions when assessing royalty terms rather than relying on a single industry-wide average.
Recent agreements also demonstrate that royalties extending into the twenties remain achievable in selected transactions, although headline rates need to be considered alongside sales thresholds, territories, development responsibilities, upfront payments and milestone structures.
“The royalty percentage is only one part of the economics of a licensing deal,” Nicholson added.“For dealmakers, the real value comes from understanding how comparable assets have been structured and what combination of financial terms has been achieved.”
Understanding the Findings in Greater Depth
The Royalty Rates in Pharmaceutical and Biotechnology Licensing Deals 2015 to 2026 report provides a substantially wider historical benchmark covering more than 1,600 disclosed licensing transactions from January 2015 through August 2026.
The report enables users to move beyond headline market trends and examine royalty rates in the context of comparable transactions, including development stage, therapy area, technology, deal structure, upfront and milestone payments, territorial rights and other financial terms.
For organizations negotiating, valuing or reviewing a licensing agreement, the report provides the underlying transaction evidence needed to assess where a proposed royalty sits within the market and, importantly, identify the deals that provide the most relevant comparables.
Qualifying purchasers may also be eligible for an Executive Customized Analysis tailored to their own business, asset, technology, pipeline or partnering priorities. This can draw on proprietary deal intelligence to highlight relevant comparable transactions, royalty benchmarks, deal structures and other market evidence aligned with the purchaser's commercial objectives.
Companies Featured in the Report
- 23andMe 2seventy bio 3a-diagnostics 3B Pharmaceuticals 3D Medicines 3SBio 4D Molecular Therapeutics 4SC 9 Meters Biopharma Aadi Bioscience Abbisko Therapeutics Abbvie AbCellera Biologics Abeona Therapeutics Abex Pharmaceutica ABL Bio Ablynx ABVC BioPharma ABX AC Immune ACADIA Pharmaceuticals Acceleron Pharma Accent Therapeutics Accord Healthcare Accro Bioscience Acelrx Pharmaceuticals Acer Therapeutics Acerus Aclaris Therapeutics Acorda Therapeutics Acrotech Biopharma Actinium Pharmaceuticals Acuitas Therapeutics Acumen Pharmaceuticals Acura Pharmaceuticals Adamis Pharmaceuticals Adaptimmune AdaptVac ADC Therapeutics Adcendo ADEL Adial Pharmaceuticals Adimab Aditx Therapeutics Adlai Nortye Adocia Adovate Aduro BioTech Advaccine Biotechnology Advanced Dosage Forms Advanz Pharma Advaxis Aegerion Pharmaceutical Aeglea BioTherapeutics Aelis Pharma Aerami Therapeutics Aerie Pharmaceuticals Aeromics Aerpio Pharmaceuticals AEterna Zentaris Aevi Genomic Medicine Aexon Labs Affibody Affimed Therapeutics AFFiRiS AFT Pharmaceuticals Agenus Bio Agios Pharmaceuticals AgNovos Healthcare ...and over 1,600 more!
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment